INNATE PHARMA SA (IPHA): Price and Financial Metrics


INNATE PHARMA SA (IPHA): $4.09

-0.06 (-1.45%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add IPHA to Watchlist
Sign Up

Industry: Biotech


Ranked

of 481

in industry

IPHA Stock Summary

  • With a one year PEG ratio of 1.07, Innate Pharma SA is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than merely 7.55% of US stocks.
  • IPHA's went public 1.51 years ago, making it older than merely 1.39% of listed US stocks we're tracking.
  • With a year-over-year growth in debt of 309.54%, Innate Pharma SA's debt growth rate surpasses 95.64% of about US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Innate Pharma SA are SLGL, PULM, VNE, INFI, and VCNX.
  • Visit IPHA's SEC page to see the company's official filings. To visit the company's web site, go to www.innate-pharma.com.

IPHA Stock Price Chart Interactive Chart >

Price chart for IPHA

IPHA Price/Volume Stats

Current price $4.09 52-week high $8.23
Prev. close $4.15 52-week low $3.55
Day low $4.08 Volume 1,580
Day high $4.15 Avg. volume 35,816
50-day MA $4.41 Dividend yield N/A
200-day MA $4.82 Market Cap 323.07M

INNATE PHARMA SA (IPHA) Company Bio


Innate Pharma SA is a biopharmaceutical company, which focuses on discovering and developing therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. Its products include immunotherapy drugs and monoclonal antibodies. The Immunotherapy drugs are designated for cancer and inflammatory diseases. The Monoclonal antibodies targets receptors and pathways controlling the activation of innate immunity cells.


IPHA Latest News Stream


Event/Time News Detail
Loading, please wait...

IPHA Latest Social Stream


Loading social stream, please wait...

View Full IPHA Social Stream

Latest IPHA News From Around the Web

Below are the latest news stories about Innate Pharma SA that investors may wish to consider to help them evaluate IPHA as an investment opportunity.

Innate Pharma to Hold its Annual General Meeting of Shareholders on May 28, 2021

The Annual General Meeting will be broadcasted live by the Company Shareholders are invited to vote at the General Meeting either by mail or by proxy Marseille, France, April 21, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) will hold its Annual General Meeting of Shareholders (“AGM”) at 11:00 a.m. CET on May 28, 2021. The Annual General Meeting will be broadcasted live. The procedures for holding the AGM have been adapted in accordance with French Ordinance No. 2020-321 of 25 March 2020 (as modified by French Ordinance n°2020-1497 of December 2, 2020) and French Decree No. 2020-418 of April 10, 2020 (as modified by French Decree No. 2020-1614 of December 18, 2020), extended by French Decree No. 2021-55 of ...

Yahoo | April 21, 2021

NUMBER OF SHARES AND VOTING RIGHTS OF INNATE PHARMA AS OF APRIL 1, 2021

Marseille, France, April 19, 2021 (GLOBE NEWSWIRE) -- Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation, Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH; Nasdaq: IPHA) releases its total number of shares outstanding as well as its voting rights as at April 1, 2021: Total number of shares outstanding:78,996,240 ordinary shares 6,806 Preferred Shares 2016 7,581 Preferred Shares 2017Total number of theoretical voting rights (1): Total number of exercisable voting rights (2):79,799,621 79,781,046 (1) The total number of theoretical voting rights (or “gross” voting rights) is used as the basis for calculating the crossing of shar...

Yahoo | April 19, 2021

Innate Pharma Reports Full Year 2020 Financial(1) Results and Business Update - Stocks News Feed

Lacutamab received PRIME designation from the European Medicines Agency in Sezary Syndrome; clinical development program advances in mycosis fungoides and peripheral T-cell lymphoma Company’s first NK cell engager selected by Sanofi as drug candidate for development Monalizumab advanced to a Phase 3 clinical trial in combination with cetuximab in IO-pretreated head and neck cancer patients;… Read More »Innate Pharma Reports Full Year 2020 Financial(1) Results and Business Update

Stocks News Feed | March 18, 2021

Innate Pharma Reports Full Year 2020 Financial(1) Results and Business Update

Lacutamab received PRIME designation from the European Medicines Agency in Sezary Syndrome; clinical development program advances in mycosis fungoides and peripheral T-cell lymphomaCompany’s first NK cell engager selected by Sanofi as drug candidate for developmentMonalizumab advanced to a Phase 3 clinical trial in combination with cetuximab in IO-pretreated head and neck cancer patients; triggered $50 million milestone payment from AstraZenecaUS and EU Lumoxiti commercialization rights returning to AstraZenecaCash position of €190.6 million2 as of December 31, 2020 MARSEILLE, France, March 18, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its consolidated financial results for the year endin...

Yahoo | March 18, 2021

Innate Pharma reports Full Year 2020 financial results and business update

Marseille, March 18, 2021 (GLOBE NEWSWIRE) -- Lacutamab received PRIME designation from the European Medicines Agency in Sezary Syndrome; clinical development program advances in mycosis fungoides and peripheral T-cell lymphomaCompany’s first NK cell engager selected by Sanofi as drug candidate for developmentMonalizumab advanced to a Phase 3 clinical trial in combination with cetuximab in IO-pretreated head and neck cancer patients; triggered $50 million milestone payment from AstraZenecaUS and EU Lumoxiti commercialization rights returning to AstraZenecaCash position of €190.6 million2 as of December 31, 2020 Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its consolidated financial results for the year ending Decemb...

Yahoo | March 18, 2021

Read More 'IPHA' Stories Here

IPHA Price Returns

1-mo -8.09%
3-mo -8.91%
6-mo -12.42%
1-year -44.28%
3-year N/A
5-year N/A
YTD 0.00%
2020 -36.49%
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.9494 seconds.